Viridian Therapeutics, Inc. (MGEN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Innoviva, Inc.

Collegium Pharmaceutical, Inc.

Viridian Therapeutics, Inc.

Amneal Pharmaceuticals, Inc.

Ardelyx, Inc.

NewAmsterdam Pharma Co. NV

REGENXBIO, Inc.

Arcturus Therapeutics Holdings, Inc.

Pharvaris NV

POINT Biopharma Global, Inc.

Intercept Pharmaceuticals, Inc.

Why is Viridian Therapeutics, Inc. ?

Positive results in Jun 25

NET PROFIT(HY) Higher at USD -187.65 MM
RAW MATERIAL COST(Y) Fallen by -51.31% (YoY)
CASH AND EQV(HY) Highest at USD 1,199.99 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 63.24%, its profits have fallen by -34.4%

Market Beating Performance

The stock has generated a return of 63.24% in the last 1 year, much higher than market (S&P 500) returns of 15.98%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Viridian Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Viridian Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Viridian Therapeutics, Inc.

46.95%

3.07

53.00%

S&P 500

13.99%

0.81

19.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-34.49%

EBIT Growth (5y)

-253.23%

EBIT to Interest (avg)

-106.87

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.98

EV to EBIT

-1.73

EV to EBITDA

-1.73

EV to Capital Employed

-53.24

EV to Sales

582.36

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-48.51%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET PROFIT(HY)

Higher at USD -187.65 MM

RAW MATERIAL COST(Y)

Fallen by -51.31% (YoY

CASH AND EQV(HY)

Highest at USD 1,199.99 MM

DEBT-EQUITY RATIO (HY)

Lowest at -104.88 %

-24What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -309.06 MM

OPERATING PROFIT(Q)

Lowest at USD -106.45 MM

PRE-TAX PROFIT(Q)

Lowest at USD -100.73 MM

NET PROFIT(Q)

Lowest at USD -100.73 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

EPS(Q)

Lowest at USD -1.23

Here's what is working for Viridian Therapeutics, Inc.

Cash and Eqv

Highest at USD 1,199.99 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -104.88 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -51.31% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Viridian Therapeutics, Inc.

Pre-Tax Profit

At USD -100.73 MM has Fallen at -54.99%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -100.73 MM has Fallen at -54.99%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -309.06 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -106.45 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -100.73 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -100.73 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

EPS

Lowest at USD -1.23

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debtors Turnover Ratio

Lowest at 0 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio